Navigation Links
ChromaDex Receives Strategic Investment From DSM Venturing
Date:10/21/2013

IRVINE, Calif., Oct. 21, 2013 /PRNewswire/ -- ChromaDex Corp.® (OTCQB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that it has received equity financing from DSM Venturing, the corporate venture arm of Royal DSM (NYSE Euronext Amsterdam: DSM), the global life sciences and material sciences company.    

Frank Jaksch, Jr., CEO and co-founder of ChromaDex, commented, "It is with great pride and enthusiasm that we welcome DSM as a strategic investor in ChromaDex. We believe the investment demonstrates their confidence in the future of ChromaDex as well as our unique business model of acquiring and commercializing novel ingredient technologies."

Pieter Wolters, Managing Director DSM Venturing said, "We are pleased to invest in ChromaDex and thereby support Frank Jaksch and the entire ChromaDex team in the expansion of their business.  We look forward to a mutually beneficial relationship."

The financial details of the investment were not disclosed.

About DSM – Bright Science. Brighter Living™:

Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competencies in Life Sciences and Material Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM's 23,500 employees deliver annual net sales of about €9 billion. The company is listed on NYSE Euronext. More information can be found at www.dsm.com.

About ChromaDex®:

ChromaDex® is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure® pterostilbene; ProC3G™, a natural black rice containing cyanidin-3-glucoside; PURENERGY™, a caffeine-pTeroPure co-crystal; and NIAGEN™, its recently launched branded nicotinamide riboside, a novel next-generation B vitamin. To learn more about ChromaDex, visit www.chromadex.com.

Forward-Looking Statements:

Any statements that are not historical facts contained in this release are "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 ("PSLRA"), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the companies' filings with the Securities and Exchange Commission, and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the companies do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

ChromaDex Investor Contact:                                             

The Del Mar Consulting Group, Inc.
Robert B. Prag, President
858-794-9500
bprag@delmarconsulting.com

or

Alex Partners, LLC  
Scott Wilfong, President  
425-242-0891  
Scott@alexpartnersllc.com  

ChromaDex Contact:
Laura Carney, Executive Assistant
949-419-0288
laurac@chromadex.com


'/>"/>
SOURCE ChromaDex Corp.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Clinical Safety Data for ChromaDex®s Patented pTeroPure® (pterostilbene) Released at 6th World Congress on Polyphenols Applications in Paris
2. ChromaDex® Experiencing Higher Than Expected Demand For Its Recently Launched BluScience™ Line of Dietary Supplements
3. Nucletron, an Elekta Company, Receives U.S. FDA 510(k) Clearance for Esteya Electronic Brachytherapy System for Treating Skin Cancer
4. Beckman Coulter Receives FDA Clearance of AccuTnI+3 Troponin I Assay on UniCel DxI Immunoassay Systems
5. Lumena Pharmaceuticals Receives Orphan Drug Designation from US Food & Drug Administration for LUM001 in Four Rare Liver Diseases
6. MabVax Therapeutics Receives $1,750,000 Small Business Innovation Research Contract Award From The National Cancer Institute To Support Development of Novel Pancreatic Cancer Diagnostic Imaging Agent
7. B. Braun Receives FDA Approval For New Large-Volume Irrigation Containers
8. Chrysalis BioTherapeutics, Inc., Receives $1.5m from the National Cancer Institute to Mitigate Radiotherapy-Induced Brain Tissue Damage
9. B. Braun Receives FDA Approval For New Large-Volume Intravenous Containers
10. Orameds Platform Technology in Oral Delivery of Proteins Receives Patent in Russia
11. Boehringer Ingelheims investigational volasertib receives FDA Breakthrough Therapy designation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2017)... -- MedX Holdings, Inc., the manufacturer and global distributor of ... today announced the national roll out of its MedX ... standard for the treatment of low back injuries and ... How it works: MedX ... who prescribe the MedX Home Back Machine Program for ...
(Date:7/14/2017)... July 13, 2017 It should come as no ... is in the midst of a crippling opioid epidemic. ... 1999, the number of overdose deaths from opiate-based medications has ... half a million dead from 2001 to 2015". During this ... hydrocodone has similarly quadrupled, drawing a compelling link between prescription ...
(Date:7/13/2017)... Md. , July 13, 2017  New York City-based ... of pharmaceutical markets should be aware of.  From new products ... trends are detailed in a recently completed study, Potential ... 1.  Age-Driven Growth ... we have been aware of the impact the growing population ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... “Kids aren't born knowing how ... their shoes,” says Suzanne Tucker, Founder of St. Louis-based positive education company Generation Mindful. ... on Kickstarter on Monday, July 21st. , The kit uses colorful, engaging and ...
(Date:7/21/2017)... ... ... West Dermatology is pleased to announce the newest addition to their Fresno, ... will join West Dermatology’s large network of medical and cosmetic dermatology practices, bringing with ... more. She graduated from the University of Florida College of Medicine Physician Assistant Program ...
(Date:7/21/2017)... ... July 21, 2017 , ... The ... offer patients improved quality of life five years after injury, according to research ... Meeting in Toronto, Ontario, Canada. The study followed patients for five years following ...
(Date:7/20/2017)... , ... July 20, 2017 , ... TransPixel Volume 2 ... two clips in the FCPX timeline. This effect isolates horizontal and vertical lines of ... package contains either a rotating or flipping animation and can be changed using a ...
(Date:7/20/2017)... ... 2017 , ... Acute myeloid leukemia (AML) is a rare ... treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem cell transplant ... such a challenging diagnosis that requires immediate action, patients and caregivers need accessible ...
Breaking Medicine News(10 mins):